Close-Unipolar™ mapping combines the benefits of bipolar and unipolar electrograms, while avoiding the challenges of each.
Learn more: https://t.co/XyjmCXRrpU
See risk info: https://t.co/XyjmCXRrpU
Products and usage represented may not be approved or cleared in all markets.
The Sphere-9™ catheter delivers safe, effective, and durable lesions for patients with persistent AF. #SuccessSimplified#Sphere9#Epeeps
Learn more: https://t.co/K0oWdg4mZp
See risk info: https://t.co/6kiozuMsbC
Paroxysmal AF in a young patient... still symptomatic months after PVI... no wonder... elicited reproducible posterior left atrium AF TRIGGER, recorded and terminated using Sphere-9 (Affera) 🤖 see 👇🧵
Fascinating de novo atypical flutter mapped in case of severe atriopathy with @MDT_EPAblation#Affera -- mapped and terminated quickly with single PF lesion. Completed PVI and PWI. Substrate requires further evaluation. Grateful to #TimSorrell from @MDT_Cardiac and his mapping skills for pulling this case together from Friday.
@MUSC_EP@MUSCCardFellows@SeidelRebecca@RCKowalMD
What's important about this publication is not just that contact matters, but that the overall level of hemolysis is very low with PulseSelect. De Smet et al in Europace published that hemolysis is same between Farapulse and Varipulse - about 2X more than PS. Details matter.
A PFA durability study using PulseSelect™ PFA System demonstrates durable lesion formation without compromising safety. Learn more about the data presented by @Devinair#EPeeps#PFA#PulseSelect
See Risk/Benefit info: https://t.co/5RDlu3jFnX
Learn more: https://t.co/OY7nIIzMtv
We are delighted to share the first clinical experience with the Sphere-9 catheter for VT ablation. Promising results using both pulsed field and radiofrequency energy. @AndreaSarkozy @CdeAsmundis @IDoundoulakis@dogi84md@cespon_maria@HRMCBrussel
https://t.co/AEqfGioWj0
Engineered for efficiency. The PulseSelect™ Pulsed Field Ablation (PFA) catheter has the ability to sense electrograms, ablate, and pace through all 9 electrodes. #Epeeps#PFA#PulseSelect
See Risk/Benefit info: https://t.co/okgAHMrpoQ
Learn more: https://t.co/3y3W44Y7Ao
The data is here! SPHERE Per-AF IDE randomized trial one-year outcomes were presented by @EladAnter at #HRS2024.
Learn more here: https://t.co/tuERrIIM2a
#Sphere9#Affera#PFA#Epeeps"
NEW AFFERA™ EVIDENCE! Sphere-360™ catheter one-year outcomes just presented at #EHRA24.
#Sphere360#Affera#PFA#Epeeps
Learn more: https://t.co/VuKB9ShyrN
Thank you to the 100+ physicians, hospital staff, and hospitals who are setting a new standard in safety by treating 1,000+ patients globally with the PulseSelect™ PFA system!
See risk/benefit info: https://t.co/bZw6XaeCo0
Learn more: https://t.co/bZw6XaeCo0
Late-breaker coming to #EHRA24 presented by Dr. Vivek Reddy on April 8, at 7:15 a.m. ET: First-in-Human Clinical Series of a Novel Conformable "Single-Shot" Pulsed Field Ablation Catheter for Pulmonary Vein Isolation. #Sphere360#Affera#PFA#EPeeps
https://t.co/bQbOA8Tn3X
This might be the first #fluoroless CTI ablation using #Pulseselect#PFA catheter. Pt developed AFL after PFA PVI. Used #ICE to position the extended array on the CTI leading with the wire in the RV & ensure contact. First pulse terminated AFL. No spasm, no NTG needed #medinbox
Congrats @AndreasMetzner7@AndreasRillig and the group in Hamburg for publishing the first real world experience with Sphere9 and Affera Mapping and Ablation system. Wonderful to see the innovation helping patients globally #medtronicemployee#Epeeps https://t.co/Qb68onUIh8